<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852693</url>
  </required_header>
  <id_info>
    <org_study_id>SurvivApp</org_study_id>
    <nct_id>NCT03852693</nct_id>
  </id_info>
  <brief_title>Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix</brief_title>
  <acronym>SurvivApp</acronym>
  <official_title>Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix: An International Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present project is to evaluate the frequency of distant metastases and
      clinically relevant relapse and mortality, respectively, of aNEN (Neuroendocrine Neoplasms of
      the Appendix) measuring 1 - 2 cm.

      The investigators hypothesize that the mortality rate of aNET (Neuroendocrine Tumors of the
      Appendix) measuring 1 - 2cm is less than 1%. Furthermore, the investigators hypothesize that
      regional lymph node metastases of aNET measuring 1 - 2 cm are clinically not relevant and are
      not associated with reduced survival. The investigators therefore hypothesize that
      oncological right-sided hemicolectomy has no impact on long-term survival after complete
      resection of aNET measuring 1 - 2 cm and that the malignant potential quo ad vitam of these
      tumors is lower than the risk of oncological hemicolectomy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Clinically relevant relapse of aNET measuring 1 - 2 cm in a population based manner</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically relevant mortality of aNET measuring 1 - 2 cm in a population based manner</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of distant metastases in aNET measuring 1-2 cm</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of histological risk factors in aNET measuring 1 - 2 cm and qualifying for oncological right-sided hemicolectomy according to ENETS guidelines with the occurrence of regional lymph node and distant metastases</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between regional lymph node metastasis and survival in patients with aNET measuring 1 - 2 cm</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term survival after complete resection of aNET measuring 1 - 2 cm with or without oncological right-sided hemicolectomy</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Neuroendocrine Tumors of the Appendix</condition>
  <arm_group>
    <arm_group_label>Retrospective Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Histopathological review</intervention_name>
    <description>Histopathological review</description>
    <arm_group_label>Prospective Group</arm_group_label>
    <arm_group_label>Retrospective Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue blocks of deceased or distant metastatic patients.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators will include all patients with aNET measuring 1 - 2 cm and complete
        resection between 01.01.2005 and 31.12.2010 of the primary tumor.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The investigators will include all patients with aNET measuring 1 - 2 cm and complete
             resection between 01.01.2005 and 31.12.2010 of the primary tumor.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reto Kaderli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reto Kaderli, MD</last_name>
    <phone>+41 31 632 23 26</phone>
    <email>reto.kaderli@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>UHIBerne</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Appendiceal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

